Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Direxion Daily S&P 500 Bear 3X Shares ETF
SPXS
5
ProShares UltraPro Short S&P500 ETF
SPXU
US Stock MarketDetailed Quotes
PYXS Pyxis Oncology
- 1.050
- +0.010+0.96%
Trading Apr 29 13:28 ET
64.67MMarket Cap-0.80P/E (TTM)
1.055High1.020Low162.44KVolume1.040Open1.040Pre Close168.67KTurnover0.37%Turnover RatioLossP/E (Static)61.59MShares5.39052wk High0.54P/B46.56MFloat Cap0.83352wk Low--Dividend TTM44.34MShs Float19.000Historical High--Div YieldTTM3.37%Amplitude0.833Historical Low1.038Avg Price1Lot Size
Pyxis Oncology News
William Blair Maintains Pyxis Oncology(PYXS.US) With Hold Rating
William Blair Sticks to Their Hold Rating for Pyxis Oncology (PYXS)
Jefferies Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Cuts Target Price to $6
Citi Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $5
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating
Pyxis Oncology Price Target Maintained With a $8.00/Share by RBC Capital
Promising Clinical Developments and Strategic Focus Drive Buy Rating for Pyxis Oncology
Pyxis Oncology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $5 Price Target
William Blair Maintains Pyxis Oncology(PYXS.US) With Hold Rating
Pyxis Oncology (PYXS) Gets a Hold From William Blair
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Cuts Target Price to $8
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Cuts Target Price to $5
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Lowers Price Target to $5
Pyxis Oncology Analyst Ratings
RBC Cuts Price Target on Pyxis Oncology to $8 From $10, Keeps Outperform, Speculative Risk
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $7 to $10
Pyxis Oncology Is Maintained at Outperform by RBC Capital
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
